01 Harvest.
Tissue is collected through a minimally invasive liposuction procedure at the patient's hospital. This is a standard approach used in clinical practice.
Mission
We are building a new class of patient-derived tissue implants for soft tissue restoration, starting with breast reconstruction.
Why we exist
ReConstruct Bio was founded to solve a problem that has persisted for decades. Women who survive breast cancer are left with reconstruction options that are either synthetic, invasive, or both. Our technology, developed at the Wyss Institute at Harvard, forms a patient's own vascularized tissue into an implantable living construct. A living implant, made from the patient, for the patient.
How It Works
From lipoaspirate to living implant.
Three steps, refined in the lab, designed to fit existing surgical practice.
02 Build.
At the ReConstruct Bio facility, the harvested tissue is formed into a construct and vascularized using SWIFT, a proprietary 3D bioprinting technology developed at the Wyss Institute at Harvard. Over several days, the construct is perfused and matured into a vascularized implant with functional channels.
03 Restore.
The BioImplant is surgically placed using established microsurgical techniques, where it is connected to blood vessels. Once in place, the tissue integrates with the body and remodels over time.
SWIFT — Sacrificial Writing Into Functional Tissue.
SWIFT is the foundational vascularization technology behind the BioImplant. Engineered tissues require perfusable networks to support viability. SWIFT enables the formation of these networks by creating channels within a dense, living cellular matrix that can be perfused.
01
Dense Cellular Matrix
Cell aggregates are compacted into a dense, living matrix approaching the cellular density of native tissue.
02
Sacrificial Channels
A fugitive ink is written through the matrix, defining a vascular network without damaging surrounding cells.
03
Perfusable Vessels
The ink is removed, leaving behind open channels that can be perfused to support tissue viability.
Technology originated at the Wyss Institute at Harvard.
Validation & IP
Proven science. Protected technology.
Demonstrated in vivo. Layered patent coverage across the United States, Europe, China, and Australia.
Validation
- Tissue survival beyond clinically relevant viability thresholds.
- Rapid and sustained vascular integration demonstrated in vivo.
- Early engagement underway to support future reimbursement pathways.
- In preliminary studies, over 60% of breast cancer survivors preferred a living tissue approach over current reconstruction options.
- Over $2M in non-dilutive funding supporting preclinical development.
Intellectual Property
- Core construct patents issued in the US, China, and Australia.
- Additional filings covering surgical integration and implant durability.
- Technology originated at the Wyss Institute at Harvard.
Team
Built by people who've shipped before.
Regenerative medicine, biofabrication, biotech leadership, and clinical reconstruction.
Luba Perry, PhD
CEO and Co-Founder
Regenerative medicine leader with 15+ years in translational research across industry and academia. Led development of vascularized tissue platforms at the Wyss Institute from concept to in vivo validation. Trained at Harvard, MIT, BU, and the Technion.
Douglas Kahn, MBA
Executive Chairman
Biotech and tech executive with multiple company builds and exits. Co-founder and former CEO of TetraGenetics, acquired by AbCellera. Trained at Stanford and Cornell.
Gozde Basara, PhD
Lead Scientist
Biofabrication and 3D bioprinting expert with a PhD from Notre Dame. Leads development of vascularized tissue implants using patient-derived cells, from design through preclinical validation.
Samuel Lin, MD, MBA, FACS
Clinical Founder (BIDMC)
Harvard plastic surgeon specializing in microsurgery and breast reconstruction. Director of Aesthetic Surgery at BIDMC and Associate Professor of Surgery at Harvard Medical School. Leads clinical strategy and surgical integration of the BioImplant.
Advisory Board
Backed by the people we trust most.
Experts in biofabrication, vascular biology, and clinical reconstruction with deep academic and translational experience.
Jennifer Lewis, ScD
Harvard and Wyss Professor
Pioneer in biofabrication and 3D printing of functional tissues. Founder of multiple companies translating materials science into clinical applications.
Christopher Chen, MD, PhD
BU and Wyss Professor
Leader in vascular biology and tissue engineering. Expert in cellular microenvironments and translation of engineered tissues into clinical systems.
Sebastien Uzel, PhD
Head of Innovation, TreeFrog Therapeutics
Biofabrication scientist and co-inventor of the SWIFT vascularization platform. Expert in 3D bioprinting of perfusable tissue constructs.
Travis Miller, MD
Stanford Plastic Surgeon
Stanford plastic surgeon specializing in microsurgery and complex reconstruction. Advises on clinical translation and surgical integration.